Skip to main content

Correction: Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models

The Original Article was published on 16 April 2014

Correction: Stem Cell Research & Therapy 2014, 5:46

The original article contains an artifact in Fig. 6H that obscures the view of the lower-middle portion of the image. The correct original image for Fig. 6H can be viewed in this Correction article.

Fig. 6
figure 6

sNEP-NSCs reduce plaque pathology and resist degeneration in a second transgenic AD model. Neprilysin immunoreactivity in the contralateral (A) and ipsilateral (B) hippocampus of sNEP-NSC transplanted transgenic mice reveals high levels of NSC neprilysin expression in vivo. (C-D) Control NSCs, in contrast, produce little to no neprilysin following transplantation, quantified in (E). At 10 months of age, Thy1-APP mice exhibit considerable amyloidosis (6E10 labelling, green) within the hippocampus (F). However, transplantation of sNEP-NSCs significantly reduced Aβ pathology within the ipsilateral hippocampus (G). Control NSCs by comparison have no effect on Aβ levels (H-I), quantified in (J). GFP labelling (green) reveals examples of NSCs engrafted into the ipsilateral hippocampus (L, N), but not within the contralateral vehicle-injected side of the brain (K, M). In line with in vitro findings, caspase activation is reduced by expression of neprilysin (O). Little active caspase-3 immunoreactivity (red) is detected within the ipsilateral hippocampi of transgenic mice (P, R). However, caspase-3 activation (red) within sNEP-NSCs (Q) is significantly reduced versus control NSCs (S). Furthermore, levels of the presynaptic terminal marker synaptophysin (T-X) are significantly increased by sNEP-NSC transplantation (U), suggesting that neprilysin expression can reduce Aβ-induced synaptotoxicity. N = 6/group, error bars represent standard error of the mean (SEM). Scale Bar = 30 μm in A-D, 350 μm in F-I, 14 μm in K-S, 45 μm in T-W. Aβ, beta-amyloid; AD, Alzheimer’s disease; NSCs, neural stem cells; sNEP, secreted neprilysin.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Mathew Blurton-Jones.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blurton-Jones, M., Spencer, B., Michael, S. et al. Correction: Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. Stem Cell Res Ther 15, 88 (2024).

Download citation

  • Published:

  • DOI: